In the news

Unapproved Drug Initiative adds up to $30 billion in healthcare costs

Study Prices for existing drugs surge after FDA approval costing billions

An FDA program to ensure decades-old drugs finally get approved is costing billions in price hikes

Analysis casts doubt on Boston Scientific TAVR embolic protection device

Shattering myths about clinical integration

GPOs not allowing coronavirus outbreak to eclipse supply chain operations

FDA approves drug that lowers cholesterol in a new way

ASC supply chain tip of the day Prepare for shortages

6 ASC supply chain tips

The Top 5 Biosimilars Articles for the Week of February 17